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Abstract
Introduction: Patients suffering from Guillain-Barré syndrome (GBS) may frequently develop an acute respiratory
failure and need ventilatory support. Immune therapy using plasma exchange or immunoglobulins has modified
the natural course of the disease and by decreasing the length of the plateau phase, may induce a rapid
improvement in ventilatory function. However a substantial proportion of patients still require prolonged
mechanical ventilation (MV) and tracheotomy. The present study was designed to search for simple functional
markers that could predict the need for prolonged MV just after completion of immune therapy.
Methods: We analyzed the data collected in a cohort of patients with GBS admitted to the intensive care unit
(ICU) of our university hospital between 1996 and 2009. Demographic, clinical, biological and electrophysiologic
data, results of sequential spirometry, and times of endotracheal intubation, tracheotomy, and MV weaning were
prospectively collected for all patients. Sequential daily neurological testing used standardized data collection by
the same investigators all along the study period. Results were compared by single and multiple regression analysis
at admission to ICU and at the end of immune therapy, according to the need and duration of MV (≤ or > 15
days).
Results: Sixty-one patients with severe GBS were studied. Sixty-six percent required MV (median length: 24 days).
The lack of foot flexion ability at ICU admission and at the end of immunotherapy was significantly associated with
MV length > 15 days (positive predictive value: 82%; odds ratio: 5.4 [1.2 - 23.8] and 82%; 6.4 [1.4 - 28.8],
respectively). The association of a sciatic nerve motor conduction block with the lack of foot flexion at the end of
immunotherapy was associated with prolonged MV with a 100% positive predictive value.
Conclusions: In patients admitted to ICU with Guillain-Barré syndrome and acute respiratory failure, the lack of
foot flexion ability at the end of immune therapy predicts a prolonged duration of MV. Combined with a sciatic
motor conduction block, it may be a strong argument to perform an early tracheotomy.
Introduction
About 30% of patients with Guillain-Barré syndrome
(GBS) will require endotracheal intubation and mechan-
ical ventilation (MV) [1,2]. Predictors of the need for
intubation and MV at the onset of the disease or at
intensive care unit (ICU) admission have been exten-
sively studied. Data from multicenter therapeutic trials
comparing plasma exchange (PE) with intravenous
immunoglobulins (IVIgs) could document that simple
clinical and biological markers could accurately predict
these needs. Inability to walk, inability to lift one’s head,
decreased vital capacity (VC), delay between onset of
symptoms and hospital admission of less than 7 days,
and high liver enzyme levels were found to have good
predictive values [3-7].
Usually, tracheotomy is indicated in these patients
when a long duration of MV is expected. However,
immunotherapy using PE or IVIgs has changed the nat-
ural course of the disease. It decreases the duration of
the plateau phase and hastens functional recovery [1-8].
Thus, early weaning from MV may obviate the need for
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need for prolonged MV are lacking in these treated
patients. Single-center studies have shown that older age
and an underlying pulmonary disease were significant
risk factors for prolonged MV, but accurate predictors
h a v en o tb e e nd e t e r m i n e d[ 8 ] .T h u s ,p r a c t i c a l l y ,a f t e r
admission to the ICU for an acute respiratory failure,
these patients receive PE or IVIgs during the first days
of their stay. These treatments usually require 5 to
8 days to be completed and the same period of time is
needed to evaluate their effect, delaying the decision to
eventually perform tracheotomy. Delayed tracheotomy
has been shown to increase the risk of severe local and
infectious complications, especially ventilator-associated
pneumonia [9-11]. On the other hand, when performed
too early during the treatment period, tracheotomy may
be useless or pose a higher risk.
For 20 years, during which time we participated in the
multicenter trials of the French GBS Study Group, patients
have been managed in our ICU by the same physicians
and therapists in accordance with the same protocols of
treatments and repeated functional assessments. To our
knowledge, no study has been specifically dedicated to
determine, just after completion of immunotherapy, the
predictors of a long duration of MV. We designed the pre-
sent study to search for simple functional markers that
could predict the need for prolonged MV.
Materials and methods
We included in the study all patients who both were
referred to the 16-bed ICU of the Roger Salengro
University Hospital (Lille, France) between January 1996
and March 2009 and fulfilled standard clinical diagnostic
criteria for GBS. The diagnosis was always confirmed by
electromyography (EMG), which was systematically per-
formed during the first week after hospital admission.
Patients were excluded if they had nonidiopathic GBS.
Patients were transferred to our ICU from either an
emergency department or a neurological ward. Reasons
for admission were usually either a suspected or estab-
lished acute respiratory failure due to neurological
impairment of respiratory muscles.
Patients entering the ICU in acute respiratory distress
or hypercapnia were intubated without delay. In the
other cases, tracheal intubation was decided when VC
measured at the bedside was less than 20% of the pre-
dicted value. Patients were ventilated in assist-controlled
mode with repeated sequences of assisted spontaneous
breathing under physiotherapist supervision. All patients
were treated by immunotherapy with either polyvalent
high-dose IVIgs or PE (four to six procedures). Each PE
p r o c e d u r ea l l o w e dt h ee x c h a n g eo f1 . 5p l a s m am a s s ,
replaced by albumin or plasma substitutes. The IVIg
treatment regimen was always 0.4 g/kg of body weight
daily for 5 consecutive days. These treatments were com-
pleted within 8 days after admission. Additionally, during
the ICU stay, patients received symptomatic treatments
and nursing care, including systematic anticoagulation to
prevent thrombosis, early enteral nutrition, and parent-
eral vitamins. Tight glucose control was not used.
Throughout the study, the same physicians assessed
patients’ neurological condition and the same physiolo-
gist (JFH) interpreted EMG data. Respiratory function
was assessed by repeated spirometry performed at the
bedside. Spirometric measurements were done by the
same well-trained respiratory physiotherapists and
included minute ventilation, respiratory frequency, VC,
and maximal minute ventilation [12].
Weaning from MV was decided on the basis of the
results of clinical assessment and sequential spirometric
measurements. Weaning procedures followed the cri-
teria and recommendations of the 8th and 21st French
Consensus Conferences in ICU and Emergency Medi-
cine [13,14]. Weaning and extubation were usually
decided when VC was greater than 20% of the predicted
value and maximal minute ventilation was twice the
minute ventilation, after a 3- to 6-hour trial of T-tube
ventilation. The physicians in charge made the decision
to perform tracheotomy on the basis of the patient’s sta-
tus, usually when no functional and respiratory improve-
ment was observed within 10 days after completion of
immunotherapy.
The following characteristics were prospectively col-
lected for all patients: age, sex, severity of illness at
admission as assessed by the Simplified Acute Physiol-
ogy Score II (SAPS II), delays from GBS onset to hospi-
tal admission and ICU admission, and ICU length of
stay. Neurological testing used the standardized data
collection elaborated by the French Cooperative Group
on Plasma Exchange in GBS [4]. The following data
were noted: (a) weakness of the limbs, (b) deep tendon
reflex abolition in the upper and lower limbs, (c) cranial
nerve impairment, (d) weakness of trunk and respiratory
muscles (VC level and ability to lift and hold one’s head
above the bed), (e) presence of paresthesia or impaired
vibratory sensitivity in the limbs, and (f) cardiovascular
autonomic dysfunction defined as an increase or
decrease (40 mm Hg) in systolic blood pressure, sponta-
neous or induced bradycardia (heart rate decrease of
greater than 20 beats per minute), or spontaneous
tachycardia (increase to greater than 120 beats per min-
ute without fever). Cerebrospinal fluid analysis and the
following biochemical tests were performed in all
patients at ICU admission: natremia, glycemia, creatine
phosphokinase, liver enzyme, platelet count, prothrom-
bin time, and C-reactive protein levels. Standard viral
serology, including cytomegalovirus and Campylobacter
jejuni, was realized. Clinical and laboratory data were
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and thereafter when significant neurological changes
were observed. To search for significant neurological
improvement or worsening, changes in motor scores
were analyzed for all patients between admission and
completion of immune therapy. Neurological improve-
ment or worsening was defined as the reappearance or
the disappearance of a spontaneous perceptible move-
ment in one of the items of the standardized neurologi-
cal functional testing. The definite functional outcome
was assessed by walking ability (independent ambula-
tion, requiring assistance to walk, or bed-bound) at a
follow-up medical consultation 4 to 6 months after dis-
charge from the ICU. Data from electrophysiological
testing were analyzed to classify GBS as acute motor
axonal neuropathy, acute motor and sensory axonal
neuropathy, acute inflammatory demyelinating polyradi-
culoneuropathy (AIDP), or AIDP with axonal involve-
ment. Motor conduction block for sciatic nerves was
defined as an at least 50% decrease in amplitude of the
compound muscle action potential (CMAP) [15].
For the purpose of this study, we compared the
patients according to the need of MV to verify whether
our population was representative of most GBS cases
and exhibited previously known prognostic markers.
Then the group of ventilated patients (MV
+ group) was
specifically studied, and the data collected at ICU admis-
sion, at the end of immunotherapy, and 8 days after
completion of immunotherapy were extracted for each
patient. The following time periods were calculated:
time from ICU admission to tracheal intubation, time
from the end of specific treatment to MV weaning,
duration of MV, and timing of tracheotomy. MV wean-
ing was defined as definite extubation or, in tracheoto-
mized patients, when spontaneous ventilation was
obtained 24 hours daily. Finally, two subgroups were
defined according to the duration of MV (≤ or >15
days) and all of their clinical and biological data were
compared to seek for significant predictors of prolonged
MV. Prospective collection of patients’ data was
approved by the ethics committee of our university hos-
pital in 1996. Since this was a fully retrospective study
with all patients’ data rendered anonymous and accord-
ing to French law, informed consent was not requested.
Statistical methods
Descriptive analysis (frequencies for categorical data,
mean ± standard deviation, median with ranges for
numerical variables) was performed in the total popula-
tion and compared according to the need of MV and to
its duration (≤ or >15 days). Categorical variables were
compared by the chi-square test or the Fisher test when
appropriate. Continuous variables were compared by the
Mann-Witney Whitney test. Differences between groups
tested by univariate analysis were considered to be sig-
nificant for variables yielding a P value of less than 0.05.
Variables attaining a 0.05 a v a l u ew e r ei n c l u d e di na
multiple logistic regression analysis model with stepwise
selection. All statistical analyses were performed with
the SAS Software, version 8.2 (SAS Institute Inc., Cary,
NC, USA).
Results
Characteristics of the studied population
Between January 1996 and March 2009, 61 patients were
admitted to our ICU for idiopathic GBS. The main
demographic data are shown in Table 1. Demyelinating
forms of GBS were predominant (75%). The mean age
was 51.9 ± 20.5 years, and males were slightly predomi-
nant (54%). The mean SAPS II was 23 ± 16 points. The
median ICU length of stay was 19 days (range of 1 to
549). Overall, four patients died in the ICU from sudden
Table 1 Characteristics of the studied population (n = 61)
Characteristics Results
Age, years 51.9 ± 20.5
Sex, males/females 33/28
SAPS II 23.1 ± 16.8
DSH, days 5.8 ± 6.3 (median
delay: 3)
Delay between onset of symptoms and ICU
admission, days
9.8 ± 10.4 (median
delay: 6)
Mechanical ventilation, number (percentage) 40 (65)
Tracheotomy, number (percentage) 28/40 ventilated
patients (70)
ICU length of stay, days 40 ± 74 (median
length: 19)
EMG type of neuropathy, number (percentage)
AMAN 6 (10)
AMSAN 9 (15)
AIDP 33 (54)
AIDP and axonal involvement 13 (21)
Positive serology, number (percentage)
Cytomegalovirus 9 (14)
Campylobacter jejuni 14 (23)
Neurological presentation at admission to the
ICU, number (percentage)
Severe dysautonomy 19 (31)
Bilateral facial nerve palsy 25 (41)
Inability to lift one’s head above the bed 22 (36)
Bilateral lack of forearm flexion 23 (38)
Bilateral lack of elbow elevation above bed 24 (56)
Bilateral lack of foot flexion 29 (48)
Bilateral lack of foot extension 28 (46)
Data are presented as mean ± standard deviation unless otherwise stated.
AIDP, acute inflammatory demyelinating polyradiculoneuropathy; AMAN,
Acute Motor Axonal Neuropathy; AMSAN, Acute Motor and Sensory Axonal
Neuropathy; DSH, delay between onset of symptoms and hospital admission;
EMG, electromyography; ICU, intensive care unit; SAPS II, Simplified Acute
Physiology Score II.
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or from septic shock (n = 1). The mortality rates were
6.5% in the whole population and 10% in the ventilated
group. Fifty-seven patients were discharged from the ICU,
and 40 patients could be assessed during a follow-up
consultation after a median delay of 5 months. At that
time, 5% of the patients were bed-bound, 75% could walk
independently, and 20% with assistance.
Group comparisons
The study flow chart is shown in Figure 1. Forty
patients (66%) required MV with a median duration of
24 days (range of 6 to 540). The median delay between
ICU admission and intubation was 2 days. Tracheotomy
was performed in 28 patients (median delay between
tracheal intubation and tracheotomy: 14 days). In three
patients, tracheotomy was performed within days after
admission since they did not tolerate the intubation
tube (one patient) or were considered at high risk of
extubation because of severe hypoxemia and autonomic
dysfunction (two patients). These three patients survived
and were weaned before day 15. Among the 19 tracheo-
tomized patients who were assessed at a follow-up visit,
complete weaning and tracheal tube removal had been
obtained in 14 cases.
The comparison between ventilated (MV
+) and non-
ventilated (MV
-) patients was done to verify the pre-
sence of the usual markers of severity in the studied
population. The main results are shown in Table 2. MV
+ patients had a higher SAPS II (P = 0.0052) and a
longer ICU length of stay (P < 0.001). Glycemia at
admission was significantly higher in the MV
+ group
(8.07 versus 6.51 mmol/L; P < 0.01). The delay between
immunotherapy and neurological improvement was
longer (P < 0.001). As expected, the frequency of severe
autonomic dysfunction and acquired infections was dra-
matically higher in the MV
+ group. When studied with
a multiple logistic regression model, the risk of MV was
significantly increased when the patient exhibited at
least one sign of cardiovascular autonomic dysfunction
and was unable to lift his or her head above the bed
(odds ratio 10.66, 95% confidence interval [CI] 2.4 to 49;
P < 0.05 and 9.86, 95% CI 1.7 to 56; P < 0.05, respec-
tively). Concerning final functional outcome, walking
autonomy was observed without significant difference
between patients requiring MV or not. These results
were consistent with a ‘standard’ population of patients
with GBS.
To determine the predictors of prolonged MV,
patients in the ventilated group were compared accord-
ing to the duration of MV (≤ or >15 days). The main
results are shown in Table 3. There was no demo-
graphic difference concerning gender, age, SAPS II, fre-
quency of cytomegalovirus and C. jejuni infections, and
frequency of demyelinating GBS subtype. Differences in
neurological testing by standardized data collection were
searched at two time points: admission to the ICU (day
1) and end of immunotherapy (day 8 to 10). Owing to
reduced sample size, multiple logistic regression analysis
was not possible. At the ICU admission time point, only
three variables were significantly different in patients
who subsequently needed more than 15 days of MV: the
median level of VC was significantly lower (46% versus
63% of the predicted value; P <0 . 0 1 ) ,p l a s m as o d i u m
concentration was significantly lower (P < 0.05), and
foot flexion ability was more frequently lacking (35%
versus 66%; P < 0.004). No difference could be observed
in any of the other neurological clinical parameters. At
the end of immunotherapy, no difference was observed
in any of the measured clinical parameters, except for
foot flexion ability and presence of a sciatic motor con-
duction block. Worsening of the neurological motor
situation was observed in six patients in the group venti-
lated more than 15 days. In five cases, it concerned the
foot flexion ability, which disappeared between days 1
and 10. Worsening was observed in only one patient in
the group ventilated less than 15 days. The operating
characteristics of the differences in frequency of foot
flexion ability and motor conduction block were calcu-
l a t e da tt h ea d m i s s i o nt i m ep o i n ta n da tt h ee n do f
immune therapy (Table 4). At admission to the ICU and
at the end of immune therapy, lack of foot flexion ability
predicted a duration of MV of more than 15 days with a
positive predictive value of 82% (odds ratio 5.4, 1.2 to
23.6; P < 0.02 and 6.4, 1.4 to 28.8; P < 0.01, respec-
tively). A sciatic nerve conduction block was associated
with the lack of foot flexion ability in 71% of cases (P <
0.02). Conversely, the lack of conduction block was
associated with the persistence of foot flexion in 64%.
The presence of a conduction block predicted the need
of prolonged MV with a positive predictive value of 85%
(odds ratio 6.8, 1.4 to 33.5; P < 0.05). The combination
of a sciatic nerve conduction block with the lack of foot
flexion at the end of immunotherapy was associated
with a prolonged MV with a specificity of 100%.
Figure 1 Flow chart of the study. MV, mechanical ventilation.
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Our study shows that, in patients with GBS, a long
duration of MV may be predicted by means of a simple
functional marker. In our patients, the lack of foot flex-
ion ability at the end of immunotherapy was signifi-
cantly associated with an MV length of greater than
15 days. The sensitivity of this simple marker was
enhanced by the results of EMG assessment; conversely,
the association of a sciatic nerve conduction block with
the lack of foot flexion seemed highly specific of a pro-
longed duration of MV. We think this result may help
clinicians to decide whether or not tracheotomy should
be performed after completion of immunotherapy.
The patients whom we have studied were representa-
tive of severe GBS. Demographic characteristics
concerning age, sex ratio, and neurological presentation
were in accordance with most published series
[5-7,10,11]. Our study confirms the previously known
early predictive factors of MV, including inability to lift
one’s head and a decrease in VC [4,6,8,16,17]. As
expected, severe autonomic dysfunction and inability to
lift one’s head above the bed at ICU admission was were
associated with an increased risk of MV requirement. In
our study, comparison of SAPS II between ventilated
and nonventilated patients showed a significantly higher
physiological severity in patients needing MV, but there
was no score difference according to the duration of
MV.
Since the length of MV in these patients is hardly pre-
dictable, finding predictive factors of prolonged
Table 2 Comparison of patients according to mechanical ventilation requirement
Characteristics Ventilated (MV
+) patients
n =4 0
Nonventilated (MV
-) patients
n =2 1
P value
Sex, males/females 23/17 10/11 NS
Age, years 56 ± 20 46 ± 19 NS
SAPS II 28.2 ± 18.6 14.1 ± 6.8 0.0052
DSH, days 5.9 ± 6.9 5.8 ± 5.1 NS
Autonomic dysfunction, percentage 60 14 0.0006
Intensive care unit length of stay, days 40.4 13.0 0.001
EMG subtype, percentage of demyelinating type 77 71 NS
Infectious complications, percentage 85 5 0.0001
Median delay between immunotherapy and neurological improvement, days 27 4 0.001
Independent ambulation at follow-up, percentage 50 58 NS
Deaths, number (percentage) 4 (10) 0 (0) -
Data are presented as mean ± standard deviation (median) unless otherwise stated. DSH, delay between onset of symptoms and hospital admission; EMG,
electromyography; MV, mechanical ventilation; NS, not significant; SAPS II, Simplified Acute Physiology Score II.
Table 3 Comparison according to the duration of mechanical ventilation
MV ≤15 days
n =1 2
MV >15 days
n =2 8
P value
Sex, males/females 7/12 16/28 NS
Age, years 50 ± 20 56 ± 21 NS
SAPS II 35 ± 25 25 ± 15 NS
DSH, days 5.0 ± 6.3 6.2 ± 7.2 NS
Delay to improvement, days 12 ± 11 28 ± 30 0.03
ICU length of stay, days 17 ± 10 75 ± 99 0.002
Sodium at admission, mmol/L 136 ± 3.9 133 ± 3.5 0.04
Dysautonomy, number 8/12 16/28 NS
EMG subtype, percentage of demyelinating subtype 63 82 NS
Acquired infection, percentage of patients 75 96 NS
Lack of foot flexion, number (percentage)
At admission 4 (34) 18 (65) 0.01
At the end of immunotherapy 5 (42) 23 (82) 0.001
Independent ambulation at follow-up, percentage 53 49 NS
Deaths, number 2 2 -
Data are presented as mean ± standard deviation (median) unless otherwise stated. Delay to improvement refers to delay between end of immunotherapy and
first neurological improvement. DSH, delay between onset of symptoms and hospital admission; EMG, electromyography; ICU, intensive care unit; MV, mechanical
ventilation; NS, not significant; SAPS II, Simplified Acute Physiology Score II.
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multicenter randomized study including medical ICU
patients, Rumbak and colleagues [9] concluded that early
tracheotomy in those projected to need MV for more
than 14 days was associated with a reduction of acquired
pneumonias, sedation, length of MV and stay in the ICU,
and finally a reduction of hospital mortality. In the stan-
dard ICU setting, tracheotomized mechanically ventilated
patients needing prolonged MV require less sedation,
appear more comfortable, and achieve more autonomy
earlier [18,19]. Thus, knowledge of predictive factors of
prolonged mechanical support could help clinicians to
select GBS patients for early tracheotomy.
To our knowledge, the study by Lawn and Widjicks [8]
is the only one that could determine criteria of prolonged
MV in GBS patients. These authors described a score
combining VC and maximal expiratory and inspiratory
pressures, measured at admission and 12 days later. In
their study, an improvement in this pulmonary functional
score predicted an MV duration of less than 3 weeks. In
our study, we did not sequentially measure VC and maxi-
mal pressures and consequently cannot compare our
results with those of Lawn and Widjicks. We found that
the lack of foot flexion ability observed at ICU admission
and at the end of immunotherapy was significantly more
frequent in patients who needed a prolonged duration of
MV. Nearly 20% of these patients lost their foot flexion
ability between days 1 and 10, giving confirmation that
neurological status should be reassessed just after comple-
tion of immune therapy. Additionally, at that time, the
combined observation of a sciatic nerve motor conduction
block with the lack of foot flexion ability was significantly
associated with a prolonged MV with 100% specificity.
This should strongly argue in favor of performing tra-
cheotomy when these two criteria are present. Durand
and colleagues [7] found, in keeping with our findings, a
significant association between respiratory failure and neu-
rological impairment of inferior limbs. The authors
showed that peripheral neurophysiological testing was
helpful for assessing the risk of respiratory failure. The
highest risk of respiratory failure was observed in patients
who exhibited a decrease in the CMAP between the proxi-
mal and the distal common peroneal nerve. The cutoff
point found by Durand and colleagues was a 20% decrease
in CMAP. In our study, the diagnosis of motor conduction
block of the sciatic nerve was considered for a 50%
decrease. This higher severity could explain why it may
represent a good predictor of prolonged MV in our study.
However, there is no obvious link between the presence of
a peripheral conduction block and prolonged diaphrag-
matic weakness. Severe demyelination is characterized by
a pronounced decrease in motor nerve conduction veloci-
ties, increase in distal motor latencies, or presence of a
conduction block [15]. In patients with GBS, the pro-
longed impairment of foot flexion is probably evidence of
a severe neurological injury with either a major demyelina-
tion process or a secondary axonal loss. This feature will
reflect a more diffuse neurological injury or an impaired
process of nerve recovery affecting phrenic nerves as well.
Our study has clear limitations, which are linked
mainly to its retrospective and monocentric design.
Only patients with the more severe form of GBS were
admitted to our ICU, and our results cannot be
extended to less severe types of GBS. Despite these lim-
itations, we think that our population accurately reflects
most patients with severe GBS. The long recruitment
period between 1996 and 2009 is unlikely to have biased
our results, because during this time, procedures of
immunotherapy for GBS did not change, and decisions
of tracheal intubation, tracheotomy, and MV weaning
were made by using the same criteria by the same physi-
cians according to the results of standardized neurologi-
cal monitoring. We found the same risk factors of MV
requirement as reported in published data, giving confir-
mation of the similarity of our patients with populations
of GBS included in preceding larger studies. However,
owing to the low number of patients, the operating
characteristics of the functional markers predicting the
need for prolonged MV should be considered cautiously.
Conclusions
We conclude from our results that, at the end of immuno-
therapy, the lack of foot flexion ability associated with a
sciatic nerve EMG conduction block may predict a long
duration of MV and represent a strong argument to
perform tracheotomy. These results should be confirmed
by a prospective study or a comparable multicenter
retrospective study.
Table 4 Operating characteristics for prediction of prolonged mechanical ventilation (n = 40)
Predictive factor Sensitivity Specificity PPV NPV Youden
index
Odds ratio
(95% CI)
P
value
Lack of foot flexion ability at admission 0.73 0.66 0.82 0.53 0.40 5.4 (1.2-23.6) <0.02
Lack of foot flexion ability at end of immune therapy 0.82 0.58 0.81 0.58 0.40 6.4 (1.4-28.8) <0.01
Presence of a motor conduction block 0.72 0.71 0.85 0.53 0.45 6.8 (1.4-33.5) <0.05
Presence of a motor conduction block and lack of foot flexion ability at
end of immune therapy
0.56 1 1 0.39 0.56 <0.001
CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value.
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￿ In patients with Guillain-Barré syndrome and acute
neuromuscular respiratory failure, immunoglobulin
or plasma exchange therapy decreases the length of
the plateau phase and hastens functional recovery.
Prediction of a long duration of mechanical ventila-
tion may facilitate patients’ management and the
decision to perform tracheotomy.
￿ In our study, the lack of foot flexion ability at
intensive care unit admission and at the end of
immunotherapy was associated with a prolonged
duration of mechanical ventilation.
￿ The combination of a sciatic nerve conduction
block with the lack of foot flexion at the end of
immunotherapy was associated with prolonged
mechanical ventilation with a positive predictive
value of 100%.
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